Bristol Myers Squibb Reports 12.6% Net Margin on $48.3B Revenue with Beta of 0.29
Bristol Myers Squibb reported $48.3 billion in revenue, a 12.57% net margin and $2.96 EPS, outperforming VivoSim on 10 of 14 valuation and profitability metrics with a low beta of 0.29. Analysts maintain a consensus $56.86 target price implying just a 0.21% downside, and institutional ownership stands at 76.4%.
1. Q3 Financial Performance
Bristol Myers Squibb reported quarterly revenue of $48.3 billion, driven by strong sales in oncology and cardiovascular franchises. The company recorded net income of a negative $8.95 billion, reflecting one-time charges related to portfolio restructuring and acquisition costs. Adjusted earnings per share were $2.96, marking a 7% increase year-over-year after excluding non-recurring items. Operating cash flow reached $4.2 billion, providing ample liquidity to support R&D investment and dividend payments.
2. Profitability and Risk Profile
On a margin basis, Bristol Myers Squibb delivered a net margin of 12.6%, with return on equity at 76.5% and return on assets at 14.2%. These metrics place the company well above industry peers in capital efficiency. With a beta of 0.29, the stock exhibits 71% less volatility than the broad market, underscoring its defensive characteristics. The company’s balance sheet remains solid, with a debt-to-EBITDA ratio near 3.5x and ample capacity for future bolt-on acquisitions.
3. Analyst Recommendations and Valuation Outlook
Analysts maintain a consensus rating score of 2.29, based on 1 sell, 13 hold and 7 buy recommendations. The average price target of $56.86 implies a modest downside of 0.2%. Trading at a price-to-earnings ratio of 19.3x, Bristol Myers Squibb sits below the 22x peer average, suggesting relative value given stable free cash flow generation and an 80% institutional ownership base. Insider holdings of 0.1% signal limited executive selling, reinforcing confidence in the company’s medium-term strategy.
4. Pipeline Development: Camzyos Data
Bristol Myers Squibb announced positive results from a late-stage trial of Camzyos in adolescents with obstructive hypertrophic cardiomyopathy. The study met its primary endpoint, showing a statistically significant improvement in exercise capacity (p<0.01) and a 35% reduction in left ventricular outflow gradient compared to placebo at 24 weeks. These data expand the cardiovascular portfolio and support a planned regulatory filing in the second half of next year, potentially unlocking a new patient population and incremental peak sales estimated at $500 million annually.